Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study

医学 多发性骨髓瘤 观察研究 硼替佐米 人口 自体干细胞移植 流行病学 内科学 队列 移植 临床试验 回顾性队列研究 肿瘤科 外科 儿科 环境卫生
作者
Virginia Abello Polo,William Mantilla,Henry Idrobo,Claudia Sossa,Luis A. Salazar,Angela María Peña,Juan Manuel Herrera,Paola Guerrero,Daniel Espinosa,Guillermo Quintero-Vega,Isabel Munevar,Kenny Galvez,A. Henao,Rigoberto Gomez,José Domingo Saavedra,Lina Gaviria,Mónica Osuna,Maria Victoria Mateos
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:22 (6): e405-e413 被引量:1
标识
DOI:10.1016/j.clml.2021.12.009
摘要

Multiple Myeloma (MM) is a plasma cell derived clonal disorder that represents around 1% of all newly diagnosed neoplasms. Limited data regarding MM treatment in Latin America is available, and access to novel agents for a substantial portion of the population is limited by their high costs.RENEHOC is a bidirectional (retrospective and prospective) multicenter observational registry of hematological malignancies in Colombia. MM patients included up to July 2020 were analyzed on this report.890 are reported with a median follow-up of 18 months (IQR: 7-42 months). Patients were classified by age group (≤ or > 65 years). Median age at diagnosis was 67 years (IQR: 59-75 years) and 47.1% of patients were women. 709 patients (79.6%) received Bortezomib-based schemes as part of the first line. Two hundred and fifty-two patients (28.3%) were consolidated with Autologous Stem Cell Transplantation (ASCT) in first-line. ASCT consolidation and age were the main independent factors influencing outcomes; in the non-ASCT cohort, 5-year overall survival was 48.7% (CI 41.8-55.2) compared to 80.7% (CI 73-86.4) in ASCT patients.This data depicts the reality of MM in Colombia, which likely reflects other Latin American countries, where access barriers to diagnosis and treatment are echoed in advanced stage diagnosis and a low rate of transplants. These seem to negatively impact survival despite the availability of most novel drugs approved for this disease. Thus, emphasizing the paradox that prevails in most of the region: availability without equitable access.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
潮汐完成签到,获得积分10
1秒前
量子星尘发布了新的文献求助10
1秒前
阿俊1212发布了新的文献求助10
2秒前
2秒前
阿成完成签到,获得积分20
2秒前
一烟尘给一烟尘的求助进行了留言
4秒前
和敬清寂发布了新的文献求助10
5秒前
Ying完成签到 ,获得积分10
6秒前
6秒前
默默冬瓜发布了新的文献求助10
6秒前
chen发布了新的文献求助10
6秒前
7秒前
7秒前
7秒前
阿成发布了新的文献求助10
8秒前
emptyyy完成签到,获得积分10
9秒前
Awoe发布了新的文献求助10
9秒前
天地一体完成签到,获得积分10
9秒前
iNk应助清爽的乐曲采纳,获得10
10秒前
10秒前
丘比特应助开心颜采纳,获得10
11秒前
12秒前
huuun发布了新的文献求助10
12秒前
12秒前
传奇3应助chen采纳,获得10
12秒前
大模型应助标致谷菱采纳,获得10
12秒前
Steven发布了新的文献求助10
13秒前
14秒前
Epiphany~王勇胜完成签到,获得积分10
16秒前
谈舒怡发布了新的文献求助10
17秒前
17秒前
澡雪发布了新的文献求助10
18秒前
胡凤至发布了新的文献求助10
18秒前
爆米花应助fts采纳,获得10
18秒前
bixiuwu完成签到,获得积分10
19秒前
小蘑菇应助梦幻时空采纳,获得10
19秒前
酷波er应助碧蓝断天采纳,获得10
19秒前
22秒前
durian发布了新的文献求助10
23秒前
颜琪完成签到,获得积分10
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976107
求助须知:如何正确求助?哪些是违规求助? 3520330
关于积分的说明 11202435
捐赠科研通 3256819
什么是DOI,文献DOI怎么找? 1798504
邀请新用户注册赠送积分活动 877642
科研通“疑难数据库(出版商)”最低求助积分说明 806496